Barriers to Diagnosing, Treating Geriatric Cancer Patients

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this interview, Dr. Hyman Muss discusses some of the barriers to providing high-quality care to geriatric cancer patients, including the barriers to diagnosis and treatment.

In this interview, Hyman B. Muss, MD, creator of the geriatric oncology program at the UNC Lineberger Comprehensive Cancer Center, discusses some of the barriers to providing high-quality care to geriatric cancer patients, including the barriers to diagnosis and treatment, factors that prevent high-quality patient assessment, and how academic and community settings differ in their approach to treating this segment of the patient population.

Recent Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Related Content
Olverembatinib has shown promising clinical efficacy in SDH-deficient gastrointestinal stromal tumors, says Haibo Qiu, MD.

Antitumor Activity Seen With Olverembatinib in GIST Subtype

Ryan Scott
June 8th 2024
Article

Olverembatinib has shown promising clinical efficacy in SDH-deficient gastrointestinal stromal tumors, says Haibo Qiu, MD.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Long-term data from the CheckMate 9LA trial support nivolumab/ipilimumab plus chemotherapy as frontline treatment for metastatic NSCLC.

Nivolumab Combo Yields Enduring Survival Vs Chemo in Metastatic NSCLC

Morgan Bayer
June 5th 2024
Article

Long-term data from the CheckMate 9LA trial support nivolumab/ipilimumab plus chemotherapy as frontline treatment for metastatic NSCLC.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

Ritu Salani, MD;Tanios S. Bekaii-Saab, MD, FACP
June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Most treatment-related adverse effects reported with CAN-2409 plus valacyclovir in a phase 2 trial were grade 1 or 2.

Novel Adenovirus Combo Elicits Immune Responses in Stage III/IV NSCLC

Tony Berberabe, MPH
June 4th 2024
Article

Most treatment-related adverse effects reported with CAN-2409 plus valacyclovir in a phase 2 trial were grade 1 or 2.

No patients with dMMR rectal cancer enrolled on a phase 2 study required subsequent chemotherapy or radiation following treatment with dostarlimab.

Clinical CRs Seen in Entire Dostarlimab dMMR Rectal Cancer Cohort

Caroline Seymour
June 3rd 2024
Article

No patients with dMMR rectal cancer enrolled on a phase 2 study required subsequent chemotherapy or radiation following treatment with dostarlimab.